BRAINCURES

Executive Summary

BRAINCURES is a UK-based biotechnology company founded in 2017 that applies a systems biology approach and its proprietary BRAINCURES Discovery Engine (BDE) to develop precision medicines for neurological and rare brain diseases. The company aims to address the global burden of neurological disorders, which affect one in ten people worldwide, by de-risking and accelerating drug discovery and repurposing. While still in early stages as a private company with no disclosed funding or pipeline details, BRAINCURES' focus on leveraging computational biology for CNS drug development positions it within a high-need area of biotech. The company's success hinges on advancing its platform toward clinical validation and securing partnerships or financing to support its R&D efforts.

Upcoming Catalysts (preview)

• Q1 2027Advancement of lead program into preclinical development45% success
• Q4 2026Series A funding round announcement50% success
• Q2 2026Research partnership with academic or pharmaceutical entity40% success